A case of complete atrioventricular block associated with primary cardiac lymphoma reversed without cardiac pacemaker implantation

Bowen Hu*, Jian Zhao*, Xin Liang, Changzhen Ren, Na Li and Chun Liang

Abstract
Primary cardiac lymphoma (PCL) is a rare malignant lymphoma that is characteristically confined to the heart and/or pericardium. Here, the case of a 70-year-old male patient with complete atrioventricular block (AVB) associated with PCL is presented. The patient had a 10-month history of palpitation and electrocardiogram (ECG) showed a complete AVB. Additionally, trans-thoracic echocardiography indicated pericardial effusion where atypical lymphoid cells were identified by pericardiocentesis. Subsequent mediastinal lymph node biopsy revealed non-germinal centre diffuse large B-cell lymphoma. Therefore, a diagnosis of PCL was confirmed. As the patient's vital signs were stable, he was prescribed chemotherapy without pacemaker implantation. After chemotherapy, the patient achieved remission and dynamic ECG demonstrated no recurrence of AVB. The present case demonstrates that although PCL initially manifesting as complete AVB is rare, this possibility should not be ignored when a new AVB without definite aetiology is encountered. In addition, if the vital signs of the patient are stable, pacemaker implantation may be postponed until the treatment effect of chemotherapy has been assessed.

Keywords
Primary cardiac lymphoma, atrioventricular block, chemotherapy, case report, remission, pacemaker

Date received: 7 January 2022; accepted: 7 March 2022
Introduction

Primary cardiac tumours are particularly rare, with a prevalence of 0.02%, and primary cardiac lymphoma (PCL) accounts for only 1.3% of primary cardiac tumours and 0.5% of extra nodal lymphomas. The main manifestations of PCL are cardiac symptoms caused by lymphoma infiltration of the myocardium, which may be accompanied by mediastinal lymph node enlargement, pleural exudation, pulmonary embolism and other metastatic signs. Some patients with PCL may present with atrioventricular block (AVB) only, which may be easily misdiagnosed. In the present report, clinical observations are shared with the purpose of improving understanding of PCL, and providing theoretical and empirical evidence for its clinical treatment and prognosis. The study protocol was approved by the Ethics Committee of Shanghai Changzheng Hospital and written informed consent was obtained from the patient for publication of this case and associated images. The reporting of this study conforms to CARE guidelines.

Case report

A 70-year-old male patient presented to the Department of Cardiology, Shanghai Changzheng Hospital (the Second Affiliated Hospital of Naval Medical University), Shanghai, China, in April 2021, with a 10-month history of dyspnoea and palpitation that had worsened over the previous 5 days. Symptoms lasted for a few minutes with each occurrence and alleviated after rest. Physical examination showed a regular heart sound with cardiac murmurs, and his heart sounds were dull and muffled suggesting an enlarged heart. Abdominal and respiratory system examination showed no obvious abnormalities. The white blood cell count was within normal limits, but haemoglobin and haematocrit values were reduced to 105 g/L and 32%, respectively. The electrocardiogram (ECG) showed a complete AVB (Figure 1a). Echocardiography and enhanced chest computed tomography (CT) both showed a mass lying in the left and right atrium (Figure 2 and Figure 3a). Transthoracic echocardiography showed pericardial effusion, and pericardiocentesis revealed atypical lymphoid cells, suggesting B-cell lymphoma. Results from CT-guided percutaneous biopsy of the mediastinal lymph node reported a diffuse large B-cell lymphoma with non-germinal centre type (Figure 4), and subsequent immunohistochemical analyses of lymph node biopsy tissue revealed positivity for apoptosis regulator Bcl-2, B-lymphocyte antigen CD20, B-lymphocyte antigen CD19, T-cell surface glycoprotein CD5, B-cell antigen receptor complex-associated protein alpha chain (CD79a), myc proto-oncogene protein (c-Myc), interferon regulatory factor 4 (also known as multiple myeloma oncogene 1 [MUM-1]), and paired box protein Pax-5. Positron emission tomography (PET)–CT showed space-occupying lesions in the atrium, accompanied by enlargement of multiple mediastinal lymph nodes, and pericardium lesions, all of which were considered to be lymphoma. Since all imaging examinations indicated that the lesion was confined to the mediastinum without distant metastasis, and both pericardium puncture and mediastinal lymph node biopsy found diffuse large B lymphoma cells, the final diagnosis was PCL. Of note, AVB is regarded as a significant clinical manifestation of PCL.

Considering that the vital signs of the patient were stable (temperature, 36.2°C; blood pressure, 123/74 mmHg; pulse, 70 beats per min; and respiratory rate, 18 breaths per min), the decision was made to prescribe initial chemotherapy without implantation of a pacemaker, and to observe whether the complete AVB would disappear.
The patient was transferred to the haematology department of Shanghai Changzheng Hospital (the Second Affiliated Hospital of Naval Medical University) to receive a chemotherapy regimen of dose-adjusted (DA)-etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (EPOCH) plus rituximab, supplemented with related supportive therapy (hydration, antacids and antiemetics). After two cycles of chemotherapy, his symptoms had relieved and repeat ECG showed a relatively normal signal with occasional atrial or ventricular premature beats and without compete AVB (Figure 1b). After five cycles of chemotherapy, the patient achieved complete remission, and repeat enhanced chest CT indicated a much smaller mass in the pericardium than before treatment (Figure 3b).

Figure 1. Representative 12-lead electrocardiograms from a 70-year-old male patient diagnosed with complete atioventricular block associated with primary cardiac lymphoma: (a) before and (b) after treatment.
The patient was regularly followed-up, and at 6 months after treatment, he had no recurrence of his initial symptoms.

**Discussion**

Primary cardiac lymphoma is relatively rare, accounting for less than 2% of cardiac tumours and 0.5% of extra nodal lymphomas, and is more common in the elderly and in male patients. Symptoms of PCL vary, and arrhythmia, ranging from premature atrial beats to complete AVB, can act as the first manifestation. The right side of the heart seems to be more often involved than the left. Therefore, it is easily misdiagnosed and patients with suspected PCL should be examined.

**Figure 2.** Representative echocardiography image from a 70-year-old male patient diagnosed with complete atrioventricular block associated with primary cardiac lymphoma, showing a mass located in the atria and atrial septum.

**Figure 3.** Enhanced chest computed tomography images from a 70-year-old male patient diagnosed with complete atrioventricular block associated with primary cardiac lymphoma: (a) before treatment, showing a mass in the atria; and (b) after treatment, showing a reduction in the size of the mass.
The current patient presented with non-specific dyspnoea on exertion and palpitation, and echocardiography and chest CT showed a mass in the atria. Information about the location and morphology of lesions occupying the pericardium, and the relationship with surrounding structures, can be provided by echocardiography, chest CT and magnetic resonance imaging. A final diagnosis may only be made by histological evaluation of the tumour. In the present case, CT was used to explore the cardiac mass and mediastinal lymphadenopathy. Finally, CT-guided percutaneous biopsy of mediastinal lymph nodes confirmed the diagnosis of lymphoma. The prognosis of patients with cardiac lymphoma is usually poor, with a median survival time of approximately 12 months. Rapid progression of cardiac involvement and generally late diagnosis are the main factors affecting prognosis. Thus, timely diagnosis and treatment is key to improving patient survival.

As previously mentioned, PCL with complete AVB as the first manifestation is extremely rare, and related treatment experience is scarce, with only a few case reports describing AVB as a major clinical presentation of PCL. Most of these patients received either a permanent or temporary pacemaker, but a few patients with stable haemodynamics did not receive pacemaker implantation. All of the patients underwent chemotherapy and prognosis varied. In the present case, although the patient had a complete AVB, his vital signs and haemodynamics were stable. Therefore, chemotherapy was selected for initial treatment, with a view of making the decision regarding whether to implant a pacemaker upon review of the post-chemotherapy ECG. Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) and DA-EPOCH chemotherapy regimens both represent treatment options for aggressive lymphoma. The DA-EPOCH regimen is indicated to exhibit excellent efficacy for aggressive diffuse large B-cell lymphoma and is expected to become the first-line treatment for high-risk diffuse large B-cell lymphoma. Hence, the patient in the present case received DA-EPOCH chemotherapy, and complete remission was eventually achieved. In addition, the dynamic ECG indicated an absence of complete AVB and, therefore, it was unnecessary to implant a pacemaker. The patient was followed-up regularly in the haematology department and his condition remained stable.
In summary, PCL should be included in the differential diagnosis when identifying the aetiology of new onset AVB. Early imaging examination and timely histopathological diagnosis are very important in diagnosing PCL. The present case describes a patient with PCL whose primary clinical presentation was complete AVB, and provides a feasible treatment modality for this type of disease.

Acknowledgements
The authors thank Dr Yafei Geng, Dr Yao Sun and Dr Xiaomin Yang for offering the pathological images, medical imaging and transthoracic echocardiography images, respectively.

Author contributions
Bowen Hu and Jian Zhao collected the data and wrote the manuscript; Na Li and Xin Liang provided relative details of the case; and Changzhen Ren was involved in managing the case. All authors have read and approved the submitted manuscript.

Declaration of conflicting interest
The Authors declare that there is no conflict of interest.

Funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

ORCID iDs
Bowen Hu https://orcid.org/0000-0003-0908-4565
Jian Zhao https://orcid.org/0000-0002-8567-5925

References
1. He S, Cao Y, Qin W, et al. Prevalence of primary cardiac tumor malignancies in retrospective studies over six decades: a systematic review and meta-analysis. Oncotarget 2017; 8: 43284–43294.
2. Antoniades L, Eftychiou C, Petrou PM, et al. Primary cardiac lymphoma: case report and brief review of the literature. Echocardiography 2009; 26: 214–219.
3. Montiel V, Maziers N and Dereme T, et al. Primary cardiac lymphoma and complete atrio-ventricular block: case report and review of the literature. Acta Cardiol 2007; 62: 55–58.
4. Gagnier JJ, Kienle G, Altman DG, et al. The CARE guidelines: consensus-based clinical case reporting guideline development. Headache 2013; 53: 1541–1547.
5. Jeudy J, Burke AP and Frazier AA. Cardiac lymphoma. Radiol Clin North Am 2016; 54: 689–710.
6. Miguel CE and Bestetti RB. Primary cardiac lymphoma. Int J Cardiol 2011; 149: 358–363.
7. Serra V, De Luca F, Savino K, et al. Syncope and cardiac tamponade: multimodality imaging of primary cardiac lymphoma. J Cardiovasc Echogr 2021; 31: 42–44.
8. Chiba A, Kawano H, Tsuneto A, et al. Multimodality imaging of cardiac lymphoma. Circ Rep 2020; 2: 209–210.
9. Sultan I, Aranda-Michel E, Habertheuer A, et al. Long-term outcomes of primary cardiac lymphoma. Circulation 2020; 142: 2194–2195.
10. Cho SW, Kang YJ, Kim TH, et al. Primary cardiac lymphoma presenting with atrioventricular block. Korean Circ J 2010; 40: 94–98.
11. Crisel RK, Knight BP and Kim SS. Reversible, complete atrioventricular block caused by primary cardiac lymphoma in a nonimmunocompromised patient. J Cardiovasc Electrophysiol 2012; 23: 1386–1389.
12. Chiba Y, Oka K, Saito H, et al. Primary cardiac B-cell lymphoma presented as heart tamponade and atrioventricular block: a case report. Acta Cytol 2010; 54: 79–81.
13. Tai CJ, Wang WS, Chung MT, et al. Complete atrio-ventricular block as a major clinical presentation of the primary cardiac lymphoma: a case report. Jpn J Clin Oncol 2001; 31: 217–220.
14. Tanaka Y, Yamabe H, Yamasaki H, et al. A case of reversible ventricular tachycardia and complete atrioventricular block
associated with primary cardiac B-cell lymphoma. *Pacing Clin Electrophysiol* 2009; 32: 816–819.

15. Amin A, Chitsazan M, Ghavidel AA, et al. A rare cause of complete heart block in an adult: Primary cardiac lymphoma. *Asian Cardiovasc Thorac Ann*. Epub ahead of print 16 March 2021; DOI: 10.1177/02184923211001697.

16. Morgan HP, El-Nayir M, Jenkins C, et al. Complete heart block as a herald sign for cardiac lymphoma. *BMJ Case Rep* 2021; 14: e239356.

17. Jang GW, Chung H, Kim WS, et al. Primary cardiac lymphoma manifesting as an atrioventricular block in a renal transplantation recipient. *JACC Case Rep* 2020; 2: 600–603.

18. Wang TL, Lai CH, Liou JY, et al. Complete AV block and Torsades de Pointes in a case of primary cardiac T-cell lymphoma. *Acta Cardiol Sin* 2015; 31: 245–248.

19. Bulum J, Banfić L, Strozzi M, et al. Primary cardiac lymphoma presenting as atrial flutter and total heart block. *Heart Vessels* 2007; 22: 52–54.

20. Matsuda S, Suzuki R, Takahashi T, et al. Dose-adjusted EPOCH with or without rituximab for aggressive lymphoma patients: real world data. *Int J Hematol* 2020; 112: 807–816.

21. Ma Q, Chang Y, Li L, et al. Efficacy of dose-adjusted EP OCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with MYC, BCL2/BCL6 gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study. *Cancer Manag Res* 2019; 11: 1363–1372.